Skip to content
Screener

Replimune Group REPL EPS (Diluted)

EPS (Diluted) at other companies

Amgen logo
AmgenAMGN
$4.37+64.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.23-4.5%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
-$0.14-208%
Regenxbio logo
RegenxbioRGNX
$0.43+131%
Immunome logo
ImmunomeIMNM
-$0.48+7.7%
CG Oncology logo
CG OncologyCGON
-$0.90-66.7%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$1.01B+160%
Enterprise value$967.91M+162%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Replimune Group’s 10-Q, filed February 3, 2026.

Filed
Feb 3, 2026, 8:12 AM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q4 2025
Accession
0001628280-26-004805
Line itemThree Months Ended December 31, 2025Three Months Ended December 31, 2024Nine Months Ended December 31, 2025Nine Months Ended December 31, 2024
Interest expense on debt obligations(1,466)(1,450)(4,429)(4,314)
Other (expense) income, net(580)(3,281)(865)(850)
Total other income (expense), net6272545,5479,707
Loss before income taxes$(71,241)$(65,765)$(241,034)$(172,592)
Income tax (benefit) provision(311)$575$(311)$575
Net loss$(70,930)$(66,340)$(240,723)$(173,167)
Net loss per common share, basic and diluted$(0.77)$(0.79)$(2.62)$(2.25)
Weighted average common shares outstanding, basic and diluted92,187,58183,498,89291,874,48177,113,695

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Replimune Group's EPS (diluted)?
Replimune Group (REPL) reported EPS (diluted) of -$0.77 in Q4 2025.
How has Replimune Group's EPS (diluted) changed year-over-year?
Replimune Group's EPS (diluted) increased by 2.5% year-over-year, from -$0.79 to -$0.77.
What is the long-term trend for Replimune Group's EPS (diluted)?
Over 3 years (2022 to 2025), Replimune Group's EPS (diluted) has grown at a 10.7% compound annual growth rate (CAGR), from -$2.26 to -$3.07.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Replimune Group's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude